Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma.

José-Francisco Garcia1, Giovanna Roncador, Juan-Fernando García

  • 1Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Centre (CNIO), Madrid, Spain. jgarcia@cnio.es

Haematologica
|April 6, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AID and MUM1 Negativity Identifies a Prognostically Favorable Subgroup of Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With Double-Hit MYC and BCL2 or BCL6 and Triple Hit.

Pathology international·2026
Same author

DNA methylation-based classification of hematolymphoid neoplasms.

Blood advances·2026
Same author

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.

Molecular cancer·2026
Same author

Peritoneal Mesonephric-Like Adenocarcinoma Arising in Endometriosis: Case Report and Review of the Literature Expanding the Spectrum of Extrauterine Mesonephric-Like Adenocarcinomas.

International journal of surgical pathology·2026
Same author

Endometrioid Intraepithelial Neoplasia in the Secretory Phase: Morphologic and Biomarker Diagnostic Features in a Common, Overlooked Setting.

The American journal of surgical pathology·2026
Same author

Endometrioid Versus Seromucinous Borderline Ovarian Tumors: Divergent Molecular Signatures and a Shared Role as Precursors to Endometrioid Carcinoma.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2026

The PRDM1 protein is crucial for plasma cell differentiation. While often positive in B-cell lymphomas, its unexpected expression in some diffuse large B-cell lymphomas correlates with aggressive behavior and poorer survival.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • The PRDM1 gene encodes the BLIMP-1 transcriptional repressor, essential for B-lymphocyte terminal differentiation and plasma cell development.
  • PRDM1 plays a critical role in regulating the differentiation pathways of immune cells.

Purpose of the Study:

  • To investigate the expression patterns of the PRDM1 protein in various normal and neoplastic lymphoid cells.
  • To correlate PRDM1 expression with specific lymphoma subtypes and clinical outcomes.

Main Methods:

  • Utilized a monoclonal antibody for PRDM1 detection in paraffin-embedded tissue sections.
  • Analyzed 679 cases of B-cell and T-cell lymphomas using tissue microarrays.

Main Results:

Related Experiment Videos

  • PRDM1 expression was confirmed in multiple myeloma, plasmacytoma, lymphoplasmacytic lymphoma, and oral plasmablastic lymphoma.
  • PRDM1 was detected in 15% of chronic lymphocytic leukemia/small lymphocytic lymphoma, 43% of diffuse large B-cell lymphoma, 41% of classical Hodgkin's lymphoma, and 23% of T-cell lymphomas.
  • A subset of diffuse large B-cell lymphoma cases showed PRDM1 expression without plasmablastic features, correlating with more aggressive disease.

    • Conclusions:

    • PRDM1 is a marker for plasmablastic differentiation in B-cell neoplasms.
    • Unexpected PRDM1 expression in certain diffuse large B-cell lymphomas, co-expressing BCL-6 and MUM1/IRF4, indicates incomplete plasmacytic differentiation and is associated with aggressive behavior and reduced failure-free survival.
    • PRDM1 expression alone is insufficient to induce a full plasma cell differentiation program in diffuse large B-cell lymphoma.